Compare Vanguard Total Stock Market Index Fund ETF (VTI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Stock Market Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Total Stock Market Index Fund ETF trades at $381.97, while Zimmer Biomet Holdings Inc trades at $97.04 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| VTI | ZBH | |
|---|---|---|
52-Week High | $381.78 | $107.71 |
52-Week Low | $311.68 | $79.58 |
Market Cap | — | $18.55B |
Sector | — | Health |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTI trades at $381.95, up 0.08% today, with a bullish technical signal driven by moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The ETF offers broad diversification with over 3,500 holdings and a low 0.03% expense ratio, as noted by The Motley Fool on August 11, 2026. Recent institutional activity includes mixed buying and selling, with a dividend scheduled for June 30, 2026.
Outlook remains positive for long-term investors due to low costs and market-wide exposure, but risks include market volatility and concentration in large-cap tech. Analyst sentiment is generally favorable, emphasizing VTI's role in foundational portfolios, though current high RSI levels indicate potential near-term pullbacks.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
